Skip to main content
PMC home page
Springer logoLink to Springer
. 2021 May 12;100(7):1917–1918. doi: 10.1007/s00277-021-04545-5

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Michael Heuser 1,✉, B Douglas Smith 2, Walter Fiedler 3, Mikkael A Sekeres 4, Pau Montesinos 5,6, Brian Leber 7, Akil Merchant 8, Cristina Papayannidis 9, José A Pérez-Simón 10, Caroline J Hoang 11, Thomas O’Brien 11, Weidong Wendy Ma 11, Mirjana Zeremski 11, Ashleigh O’Connell 11, Geoffrey Chan 11, Jorge E Cortes 12,13
PMCID: PMC8496603  PMID: 33978823

Correction to: Annals of Hematology https://doi.org/10.1007/s00277-021-04465-4

Due to an oversight during the preparation of figures for manuscript submission, the numbers of patients at risk were omitted from the bottom of Fig. 1, panel C. These have now been added along the x-axis to ensure that readers have the most complete information regarding the analysis shown.

Fig. 1.

Fig. 1

Open in a new tab

Kaplan–Meier plots of overall survival in the a overall population, b de novo AML subgroup, c secondary AML subgroup, and d overall population censoring for patients receiving follow-up HMAs. GLAS, glasdegib; mo, months; mOS, median overall survival

The original article has been corrected.

Articles from Annals of Hematology are provided here courtesy of Springer

RESOURCES